Literature DB >> 31228530

Characterizing dupilumab facial redness: A multi-institution retrospective medical record review.

Reid A Waldman1, Madeline E DeWane1, Brett Sloan2, Jane M Grant-Kels1.   

Abstract

Entities:  

Year:  2019        PMID： 31228530     DOI： 10.1016/j.jaad.2019.06.026

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  13 in total

1.  Real-World Effectiveness and Safety of Dupilumab for the Treatment of Moderate to Severe Atopic Dermatitis in Indian Patients: A Multi Centric Retrospective Study.

Authors:  Sandipan Dhar; Abhishek De; Sahana M Srinivas
Journal:  Indian J Dermatol       Date:  2021 May-Jun       Impact factor: 1.494

2.  Facial erythema after the treatment of dupilumab in SLE patient.

Authors:  Dong Hyek Jang; Jae In Lee; Joo Yoon Bae; Hye Jung Jung; Mi Yeon Park; Jiyoung Ahn
Journal:  Allergy Asthma Clin Immunol       Date:  2020-07-03       Impact factor: 3.406

Review 3.  Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review.

Authors:  Paul C Macklis; Brittany Dulmage; Brady Evans; Misha Rosenbach; Johann E Gudjonsson; Benjamin H Kaffenberger
Journal:  Drugs R D       Date:  2020-09

4.  Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib.

Authors:  Jannett Nguyen; Jennifer K Chen; Golara Honari; Marlyanne Pol-Rodriguez; Justin M Ko; Albert S Chiou
Journal:  JAAD Case Rep       Date:  2020-11-06

Review 5.  A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.

Authors:  Masahiro Kamata; Yayoi Tada
Journal:  JID Innov       Date:  2021-07-30

6.  Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: A case report of 3 patients.

Authors:  Young Jae Kim; Mi Young Lee; Chong Hyun Won
Journal:  Asia Pac Allergy       Date:  2022-01-10

7.  Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.

Authors:  Andrew Alexis; Marjolein de Bruin-Weller; Stephan Weidinger; Weily Soong; Sebastien Barbarot; Ileana Ionita; Fan Zhang; Hernan Valdez; Claire Clibborn; Natalie Yin
Journal:  Dermatol Ther (Heidelb)       Date:  2022-03-17

8.  Dupilumab-Associated Head and Neck Dermatitis With Ocular Involvement in a Ten-Year-Old With Atopic Dermatitis: A Case Report and Review of the Literature.

Authors:  Arthur M Samia; Lyda Cuervo-Pardo; Marjorie E Montanez-Wiscovich; Vanessa Y Cavero-Chavez
Journal:  Cureus       Date:  2022-07-23

Review 9.  Atopic Dermatitis in Older Adults: A Review of Treatment Options.

Authors:  Ryoji Tanei
Journal:  Drugs Aging       Date:  2020-03       Impact factor: 3.923

10.  A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world.

Authors:  Dong Hyek Jang; Seok Jae Heo; Hyung Don Kook; Dong Heon Lee; Hye Jung Jung; Mi Yeon Park; Jiyoung Ahn
Journal:  Sci Rep       Date:  2021-12-07       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.